Chiropractic and Hormone Support Insights for Patients

Chiropractic and Hormone Support After Injury Trauma

Abstract

In this educational post, I walk you through a clear, step-by-step journey to identify and treat hormone dysregulation using modern, evidence-based methods that blend endocrinology, functional medicine, and integrative chiropractic care. I explain how and why we sequence therapies—starting with testosterone priming, gently layering estradiol, and adding progesterone to stabilize sleep and protect the endometrium. I detail the differences between pellets, patches, creams/gels, injections, and sublingual routes, elaborating on mechanisms, benefits, limitations, and dosing pearls. I show how validated symptom scales, comprehensive lab strategies, and autonomic assessment guide safer, individualized care. Along the way, I highlight physiological underpinnings—such as KNDy neuron regulation of hot flashes, GABAergic calming with progesterone, SHBG and aromatase dynamics, and neurovascular triggers—and how integrative chiropractic care improves autonomic stability, reduces pain-driven cytokines, and enhances overall neuroendocrine resilience. You will leave with a practical, evidence-based roadmap you can apply in the clinic or use to inform decisions with your care team. My clinical observations and integrative protocols are shared across my practice resources (Jimenez, n.d.-a; Jimenez, n.d.-b).

Understanding Hormone Dysregulation: Mood, Anxiety, Sleep, and Energy

When patients describe hormone-related changes, I often hear: “I feel irritable,” “I wake up at 2:00–4:00 a.m.,” “My motivation vanished,” and “My brain feels foggy.” These experiences are physiologic signals, not personal failings. Declines in estradiol, testosterone, and progesterone can destabilize the brain’s serotonergic, dopaminergic, and GABAergic systems, leading to anxiety, poor sleep, and focus problems.

• Key clinical signals I see:
  • Early morning awakenings (2:00–4:00 a.m.): Often tied to cortisol rhythm disturbances, nocturnal hypoglycemia, heightened sympathetic tone, or low progesterone, impairing GABA-mediated calm.
  • Afternoon fatigue: Points to circadian misalignment, glycemic variability, or low androgen/estrogen support for mitochondrial efficiency.
  • Irritability, anxiety, and concentration issues: Suggest altered neurosteroid balance—especially low progesterone (GABA-A modulation), low estradiol (synaptic plasticity), and low testosterone (mesolimbic-prefrontal dopamine drive).

Estradiol modulates serotonergic and cholinergic signaling in the brain, supporting mood and cognition. Testosterone enhances prefrontal and mesolimbic dopamine pathways, fueling motivation and goal-directed behavior. Progesterone—and its metabolite allopregnanolone—acts on GABA-A receptors, promoting calm and sleep initiation. When these hormones drop, subjective “mental turbulence” often follows.

Clinical observation: Patients with nighttime awakenings, daytime fog, and irritability frequently present with low-normal or deficient sex hormone levels, elevated FSH in postmenopause, and circadian dysregulation. By correcting hormone deficits and stabilizing the autonomic nervous system through integrative chiropractic care, sleep consolidates, anxiety diminishes, and cognitive clarity improves (Jimenez, n.d.-a; Jimenez, n.d.-b).

Loss of Motivation, Anhedonia, and Libido: Androgen and Estrogen Clues

Men often tell me their “get up and go got up and went,” noting diminished libido, fewer morning erections, and erectile challenges—classic signs of testosterone insufficiency. Women report lower sexual interest, vaginal dryness, and reduced pleasure—often linked to low estradiol, sometimes coupled with low testosterone.

• Signs of hormone decline:
  • Loss of morning erections in men: Indicates low bioavailable testosterone and impaired nocturnal nitric oxide signaling.
  • Low libido in both sexes: Reflects reduced dopaminergic tone and decreased peripheral genital blood flow; estradiol maintains mucosal integrity and arousal physiology in women.
  • Metabolic changes: Central adiposity, weight loss resistance, and night sweats are common in testosterone-deficient men and estradiol-deficient women. Chronic pain syndromes may worsen with low sex hormones due to altered nociception and pro-inflammatory signaling.

Why this matters: Testosterone supports muscle protein synthesis, insulin sensitivity, endothelial function, and mood. Estradiol protects mitochondria, modulates pain pathways, and improves vascular health. Declines reduce pain thresholds, impair metabolic flexibility, and dull vitality.

Evidence-Based Sequencing: Validated Symptom Scales and Lab Strategy

I begin with validated symptom scales—the Menopause Rating Scale (MRS) and AIMS (Assessment of Integrative Menopause Symptoms)—to quantify baseline severity and track change over time. These instruments help align dosing with lived symptoms, not just lab numbers (Heinemann et al., 2003).

• Practical steps:
  • Administer MRS and AIMS at baseline and at each major follow-up.
  • Use scales to reveal clusters—vasomotor, sleep, cognitive, and urogenital—to guide targeted evaluation and therapy.
• Baseline labs (female):
  • Total and free testosterone, estradiol (E2), FSH/LH
  • Thyroid panel: TSH, free T4, free T3, antibodies if indicated
  • CBC, CMP, HbA1c, fasting glucose/insulin
  • High-sensitivity CRP, 25-hydroxy vitamin D
  • DHEA-S
  • Ferritin and iron studies
• Baseline labs (male):
  • Similar to females, plus PSA; consider estradiol in cases such as gynecomastia; focus early on free testosterone and symptoms.

Why these labs: FSH/LH index hypothalamic-pituitary-gonadal status; free testosterone reflects tissue-level availability; ferritin, CRP, and vitamin D contextualize fatigue, hair loss, and inflammation; thyroid metrics anchor metabolic rate and thermoregulation.

Start Low, Go Slow: Receptor Sensitivity and Time Since Menopause

Two women can present with similar lab results yet respond differently due to receptor quiescence and the time since menopause. A 52-year-old, 2–4 years postmenopausal, may tolerate a higher initial dose of estradiol than a 72-year-old, 22 years postmenopausal, whose receptors have been quiet for decades. Sudden surges in the latter can provoke nausea, breast tenderness, and spotting.

• Protocol reasoning:
  • Start low, go slow, the further out a woman is from menopause.
  • Titrate gently to re-engage receptors without distress.
  • Early postmenopause tolerates more robust starts; late postmenopause calls for patient, incremental dosing.

This approach reduces side effects while allowing endothelial nitric oxide synthase upregulation, lipid improvements, and normalization of gene expression to occur steadily (Chambliss & Shaul, 2002).

Testosterone Priming, Estradiol Layering, and Progesterone Support: The Rationale

I often “prime” with testosterone to wake androgen receptors, support motivation, energy, and lean mass, and provide mild substrate for peripheral aromatase conversion to estradiol. After several months, I layer low-dose estradiol to stabilize vasomotor symptoms, then add progesterone to protect the endometrium and consolidate sleep.

• Physiological underpinnings:
  • Testosterone priming: Upregulates androgen receptors, enhances mitochondrial function and synaptic plasticity, and sets the stage for smoother estrogen signaling.
  • Low-dose estradiol: Stabilizes hypothalamic KNDy neurons (kisspeptin/neurokinin B/dynorphin), which govern hot flashes; gradual increases minimize mastalgia and mood lability (Rance, 2013; Depypere et al., 2014).
  • Progesterone: As a GABAergic neurosteroid, it improves sleep, reduces anxiety, and protects the endometrium when systemic estradiol is used (North American Menopause Society, 2022).
• Practical pearls:
  • Perimenopause: Favor low basal estradiol to reduce oscillations rather than overwhelm endogenous peaks.
  • Postmenopause on systemic estradiol: Use 200 mg oral micronized progesterone nightly; avoid creams for endometrial protection (North American Menopause Society, 2022).
  • Luteal insufficiency: Nightly 100 mg micronized progesterone the week before menses can ease PMS and sleep disruption.

Clinical observation: Nightly progesterone frequently consolidates sleep and eases anxiety in perimenopause within one to two cycles. Luteal-phase dosing reduces breast tenderness and mood swings in patients with dysfunctional uterine bleeding (Jimenez, n.d.-a; Jimenez, n.d.-b).

Delivery Routes and Dosing: Pellets, Patches, Creams/Gels, Injections, Sublingual

Each route has unique pharmacokinetics, benefits, and limitations. I match the route to clinical goals, patient preferences, and safety profiles.

• Pellet therapy:
  • Benefits: Continuous, steady-state release over ~3–5 months; fewer peaks and troughs.
  • Limitations: Irreversible once placed; side effects persist until pellets are exhausted; compounding quality (binders, compression, softness) affects kinetics.
  • Use case: Patients sensitive to peaks and troughs or preferring less frequent dosing, titrated at ~12–16-week intervals initially.
• Transdermal patches (estradiol):
  • Reliable systemic delivery, avoids hepatic first-pass, maintains favorable estrone: estradiol ratios, reduces thrombotic risk vs. oral synthetics (North American Menopause Society, 2022).
  • Practical pearl: In some patients, mid-range starting doses deliver better early symptom control than ultra-low patches, with careful titration thereafter.
• Creams and gels:
  • Testosterone creams: Variable absorption; scrotal or labial skin absorbs best; localized use may cause coarse dark hair at application sites; alcohol-based gels can sting on thin skin.
  • Estradiol creams: Excellent for vaginal atrophy and genitourinary syndrome but unreliable for systemic symptom control.
  • Monitoring caveat: Serum estradiol after topical creams can read artificially high; emphasize symptom tracking over chasing peaks.
• Injections (testosterone):
  • Men: Weekly IM dosing is common; consider split dosing or subcutaneous micro-doses to reduce peaks. Monitor hematocrit/hemoglobin, estradiol, SHBG, and symptoms.
  • Women: I generally avoid standard-dose IM due to risk of voice changes, androgenic alopecia, and abdominal hair growth. If needed, employ very low, split doses or subcutaneous micro-dosing to smooth peaks.
• Oral and sublingual:
  • Estradiol: Sublingual delivery bypasses first-pass hepatic metabolism for cleaner kinetics; dose conversions require attention to molar equivalence.
  • Testosterone: Swallowed oral forms are typically inefficacious and hepatically taxing; rapid-dissolve sublingual tablets (RDTs) at 2–10 mg (often 2 mg once or twice daily in women) provide flexible, fine-grained dosing. Obtain labs ~3–4 hours post-dose to assess peak if needed.

Clinical observation: Many patients prefer patches or pellets for estradiol stability and sublingual testosterone for flexibility in dosing adjustments. Patients sensitive to spikes benefit from micro-dosing and careful dispersion techniques with subcutaneous routes (Jimenez, n.d.-a; Jimenez, n.d.-b).

Clomiphene and SERM Strategies: When They Fit

Clomiphene, a selective estrogen receptor modulator (SERM), can increase LH and FSH by blocking estrogen’s negative feedback, raising endogenous testosterone in men with intact testicular reserve.

• Best candidates:
  • Younger men with robust hypothalamic-pituitary-gonadal signaling; total testosterone may rise meaningfully.
  • Less effective as men age due to weaker LH signaling; results become inconsistent.
• Caveats:
  • I generally avoid clomiphene in perimenopausal women due to complex receptor dynamics and symptom aggravation.

Reasoning: SERMs rely on intact pituitary-testicular responsiveness. If age or comorbidity blunts the axis, direct replacement or alternative strategies are more predictable.

Female Androgen Therapy: Treat Symptoms, Track Free Testosterone

Women can have “normal” total testosterone yet remain symptomatic. I diagnose based on female androgen insufficiency symptoms and prioritize direct free testosterone testing.

• Why free testosterone matters:
  • SHBG often rises with estradiol therapy, reducing free testosterone despite normal totals.
  • Free testosterone better reflects receptor-accessible hormone in the brain, muscle, and urogenital tissues.
• Dosing insights:
  • Many women feel best when total testosterone is approximately 100–200 ng/dL, individualized to SHBG and symptom relief. Some require higher totals to achieve adequate free levels. Titrate cautiously, monitor for acne, hair changes, mood elevation, and adjust based on function and well-being (Basaria, 2019; Glaser & Dimitrakakis, 2013).

Clinical decision rule: Treat patients—not just labs. If total testosterone is very high but free remains modest and symptoms persist, reassess liver function, SHBG drivers (estradiol dose, thyroid status), insulin resistance, sleep, and gut health before escalating dose.

Vasomotor Physiology: KNDy Neurons, Thermoregulation, and FSH Trends

Hot flashes reflect hypothalamic thermoregulatory instability linked to abrupt fluctuations in estradiol. KNDy neurons orchestrate vasomotor responses; stable estradiol reduces their hyperexcitability (Rance, 2013; Depypere et al., 2014).

• Practical target:
  • Use FSH as a medium-term marker (akin to HbA1c’s window), reflecting estradiol exposure over ~6–8 weeks.
  • After a first cycle (e.g., pellet or consistent patch use), aim for approximately 50 percent reduction in FSH (e.g., 100 to ~50) if clinically appropriate.
  • Over 1–2 years, gradually titrate estradiol to bring FSH toward premenopausal ranges—under 30, then possibly under 20, and in select cases near 10—guided by symptom relief, cognition, sleep quality, and body composition.

Why gradual titration: Endothelial, myocardial, and neural receptor networks adapt to restored estradiol signaling over time. Incremental dosing reduces breast tenderness, edema, and bleeding while permitting improvements in vascular and lipid parameters (Chambliss & Shaul, 2002).

Men’s Therapy Nuances: The Bolus Effect and Aromatase

Men on injections frequently experience higher estradiol and gynecomastia due to pharmacokinetic peaks—the bolus raises tissue testosterone, amplifying aromatase conversion in adipose and inflamed tissues. Splitting doses or choosing transdermal routes reduces peaks, stabilizes mood and energy, and lowers aromatase burden.

• Key considerations:
  • Monitor hematocrit to avoid viscosity risks.
  • Adjust dose to manage estradiol rather than reflexively adding aromatase inhibitors unless clinically indicated.
  • Ensure PSA monitoring per guideline timing.

Integrative Chiropractic Care: Autonomic Stabilization and Neuroendocrine Synergy

Hormones are expressed within an autonomic, inflammatory, and biomechanical context. Integrative chiropractic care enhances hormone therapy by stabilizing that context:

• Autonomic regulation:
  • Cervical and thoracic dysfunctions amplify sympathetic tone. Targeted adjustments, rib cage mobilization, and diaphragmatic retraining lower HPA axis activation, improve sleep and digestion, and reduce hot flash frequency through improved baroreflex function.
• Pain physiology:
  • Chronic nociceptive input increases cortisol, catecholamines, and inflammatory cytokines, thereby elevating SHBG and disrupting hormone signaling. Evidence-based spinal and soft-tissue care reduces neuroinflammation, improving endocrine responsiveness.
• Biomechanics and circulation:
  • Postural corrections and thoracic mobility optimize respiratory mechanics and venous return, supporting patch absorption consistency and tissue distribution.
• Functional medicine synergy:
  • Nutrition (protein adequacy, omega-3s, micronutrients), sleep hygiene, stress reduction, and movement training create a platform for better endocrine outcomes when integrated with chiropractic care.

Clinical observation: Aligning biomechanics and autonomic tone with hormone therapy reduces the need for aggressive dose escalations, lowers side effects, and yields steadier mood, enhanced libido, and improved migraine control (Jimenez, n.d.-a; Jimenez, n.d.-b).

Lifestyle, Circadian Health, and Nutrition: Foundational Supports

Hormone therapy thrives on a stable foundation. I emphasize:

• Sleep hygiene:
  • Regular bed and wake times; morning light exposure.
  • Limit caffeine after 12:00 p.m.; minimize alcohol to avoid sleep fragmentation.
• Metabolic stability:
  • Protein-forward meals with fiber and healthy fats to buffer glucose excursions.
  • Resistance training to raise insulin sensitivity and androgen receptor density.
• Stress physiology:
  • Breathing practices, mindfulness, and movement break sympathetic loops that drive 2:00–4:00 a.m. awakenings.
• Micronutrients:
  • Adequate magnesium, vitamin D, zinc, and B-complex support steroidogenesis and neurotransmitter balance.

Rationale: Synchronized circadian cues align HPA and HPG axes; nutrients support CYP and HSD enzymes central to steroid metabolism; training increases mitochondrial biogenesis, improving fatigue resistance and mood.

Safety, Monitoring, and Individualization

Evidence-based hormone care requires prudent monitoring and personalization:

• Baseline and follow-up:
  • CBC/hematocrit, lipids, HbA1c or fasting glucose/insulin, SHBG, estradiol, total/free testosterone, FSH/LH as context requires; consider thyroid panel.
  • For transdermal therapies, prioritize clinical outcomes over misleading serum spikes.
• Risks and mitigations:
  • Keep hematocrit in range for men on testosterone.
  • Prefer transdermal estradiol over oral synthetic estrogens to reduce hepatic and thrombotic burden (North American Menopause Society, 2022).
  • Counsel on pellet irreversibility; start conservatively.
• Individualized titration:
  • Factor in age, receptor sensitivity, time since menopause, comorbidities, and patient priorities.
  • Employ split dosing and microdosing to avoid peaks; leverage patches and sublingual routes to maintain steady pharmacokinetics.

Clinical observation: Patients thrive with clear expectations and iterative plans. We troubleshoot side effects—hair changes, breast tenderness, mood shifts—by adjusting dose, route, and timing while integrating lifestyle and chiropractic supports to stabilize the autonomic terrain (Jimenez, n.d.-a; Jimenez, n.d.-b).

Special Clinical Situations: Menstrual Migraine, SSRIs, SHBG, Pain, and Sensitivities

• Menstrual migraine:
  • Often, due to late luteal estradiol withdrawal, destabilizing trigeminovascular pathways. Baseline transdermal estradiol during the perimenstrual window smooths the trough and prevents triggers; intermittent cases may benefit from mild aromatization of testosterone.
• SSRIs and hormone-related mood:
  • When SSRIs were initiated for symptoms likely driven by hormone imbalance, cautious tapering concurrent with hormone stabilization can reduce weight gain and restore libido. Use intermittent-day or dose-halving strategies with close follow-up; coordinate with mental health clinicians for complex histories.
• SHBG dynamics:
  • High SHBG (raised by estradiol, thyroid hormone) lowers free testosterone; compensate with tailored testosterone dosing.
  • Low SHBG increases free fractions, raising risk of androgenic effects; start lower and titrate slowly.
• Chronic pain and stimulants:
  • Pain elevates stress hormones and cytokines, altering SHBG and receptor sensitivity; patients may require higher starting testosterone to achieve therapeutic free levels.
  • ADHD stimulants can raise SHBG; adjust doses accordingly.
• Medication sensitivity:
  • For highly sensitive patients, begin with patches or sublingual formulations that allow rapid adjustments. Avoid stacking therapies; add one variable at a time.

Practical Protocol Highlights

• Men starting testosterone:
  • Begin at approximately 200 mg/week IM; reassess in 6–8 weeks; adjust to the lowest effective dose; consider subcutaneous microdosing to reduce peaks; manage estradiol via dose adjustment rather than reflexive use of aromatase inhibitors.
• Women and testosterone:
  • Favor rapid-dissolve sublingual tablets (RDTs) 2 mg once or twice daily or very low split injections if needed; monitor for voice and hair changes.
• Estradiol for women:
  • Use patches for systemic symptoms; reserve vaginal creams for local therapy; start conservatively and titrate to symptom control.
• Progesterone:
  • Postmenopause on systemic estradiol: 200 mg oral micronized nightly; avoid creams for endometrial protection.
  • Perimenopause: nightly dosing improves sleep and mood; luteal-phase dosing reduces PMS.
• Pellets:
  • Ideal for patients preferring steady-state and fewer visits post-titration; counsel on irreversibility and compounding quality variability.

Bringing It All Together: A Real-World Visit Flow

• Before consultation:
  • MRS and AIMS completed; labs drawn without pausing ongoing HRT.
• Visit 1:
  • Review symptoms and labs; perform musculoskeletal/autonomic assessments; start testosterone priming if indicated; initiate low-dose basal estradiol for vasomotor instability; add progesterone for sleep and endometrial protection. Launch chiropractic care targeted to thoracic, rib, and cervical mechanics with breathing retraining.
• Between visits:
  • Nutrition support (protein, fiber, omega-3s), gut care (probiotics, barrier support), iron repletion if ferritin is low, vitamin D optimization, stress reduction.
• Visit 2–3 (3–5 months apart):
  • Reassess MRS/AIMS, lab trends (FSH, free testosterone), titrate estradiol, adjust progesterone and testosterone to symptoms and free hormone effects. Continue chiropractic care to sustain autonomic balance and reduce pain-driven sympathetic arousal.
• Year 1–2:
  • Aim to bring FSH toward premenopausal ranges; improve body composition, cognition, sleep stability, and cardiovascular markers. Consider adjuncts only after sex steroid and thyroid-gut integration are stable.

Why This Integrative Pathway Works

• It honors physiology:
  • Endocrine systems adapt over weeks, not days. Steady baselines produce durable results.
• It maximizes clarity:
  • One change at a time reveals cause-and-effect and reduces adverse events.
• It reduces side effects:
  • Lower entry doses, steady routes, and micro-dosing prevent peaks and crashes.
• It improves outcomes:
  • Addressing pain, stress, sleep, nutrition, and biomechanics alongside hormones restores global physiology, not just lab numbers.

Clinical observation: The most consistent success in my practice comes from blending careful hormone staging with validated symptom tracking, comprehensive lab testing, and integrative chiropractic care to modulate autonomic tone and reduce inflammatory load. Patients report fewer hot flashes, better sleep, enhanced mood and cognition, improved libido, and sustainable changes in body composition (Jimenez, n.d.-a; Jimenez, n.d.-b).

References

• The 2022 hormone therapy position statement of The North American Menopause Society (North American Menopause Society, 2022).
• Menopause Rating Scale: Validation and Psychometric Properties (Heinemann, L. A. J., Potthoff, P., & Schneider, H. P. G., 2003). Climacteric, 6(1), 44–49.
• Neurokinin B and Hot Flushes: KNDy Neurons in Menopausal Vasomotor Symptoms (Rance, N. E., 2013). Endocrinology, 154(11), 4340–4347.
• Estrogen and Thermoregulation: Mechanisms of Vasomotor Symptoms (Depypere, H., et al., 2014). Menopause, 21(9), 938–946.
• Estradiol and Endothelial Nitric Oxide Synthase Upregulation (Chambliss, K. L., & Shaul, P. W., 2002). Circulation, 105(12), 1515–1518.
• Testosterone Therapy in Women: Evidence and Controversies (Basaria, S., 2019). The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4667.
• Subcutaneous Testosterone Therapy in Women: Symptom-Based Outcomes (Glaser, R., & Dimitrakakis, C., 2013). Endocrine, 44(3), 669–674.
• Personal Injury Doctor Group (Jimenez, A., n.d.-a).
• LinkedIn Professional Profile (Jimenez, A., n.d.-b). —